Advertisement
Australia markets close in 5 hours 44 minutes
  • ALL ORDS

    7,962.10
    -12.70 (-0.16%)
     
  • ASX 200

    7,712.00
    -12.30 (-0.16%)
     
  • AUD/USD

    0.6616
    -0.0001 (-0.02%)
     
  • OIL

    78.26
    -0.19 (-0.24%)
     
  • GOLD

    2,340.50
    -8.60 (-0.37%)
     
  • Bitcoin AUD

    100,679.01
    +605.84 (+0.61%)
     
  • CMC Crypto 200

    1,385.89
    -31.98 (-2.26%)
     
  • AUD/EUR

    0.6179
    +0.0001 (+0.01%)
     
  • AUD/NZD

    1.0780
    +0.0015 (+0.14%)
     
  • NZX 50

    11,818.24
    -46.65 (-0.39%)
     
  • NASDAQ

    19,659.80
    +82.90 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.68 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.82 (-0.94%)
     
  • NIKKEI 225

    38,371.19
    -443.37 (-1.14%)
     

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com